NASDAQ:PCYC - Pharmacyclics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pharmacyclics logoPharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.

Receive PCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for PCYC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:PCYC
CUSIP71693310
WebN/A
Phone+1-302-6587581

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins2.02%
Return on Equity1.93%
Return on Assets1.52%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

The Truth About Cryptocurrencies

Pharmacyclics (NASDAQ:PCYC) Frequently Asked Questions

What is Pharmacyclics' stock symbol?

Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC."

How were Pharmacyclics' earnings last quarter?

Pharmacyclics, Inc. (NASDAQ:PCYC) issued its quarterly earnings results on Friday, May, 1st. The biopharmaceutical company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.02. The biopharmaceutical company had revenue of $206 million for the quarter, compared to analysts' expectations of $226.27 million. Pharmacyclics had a return on equity of 1.93% and a net margin of 2.02%. View Pharmacyclics' Earnings History.

Has Pharmacyclics been receiving favorable news coverage?

News articles about PCYC stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pharmacyclics earned a media sentiment score of 0.19 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.27 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Pharmacyclics?

Shares of PCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Pharmacyclics?

Pharmacyclics' mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581.


MarketBeat Community Rating for Pharmacyclics (PCYC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  415 (Vote Outperform)
Underperform Votes:  358 (Vote Underperform)
Total Votes:  773
MarketBeat's community ratings are surveys of what our community members think about Pharmacyclics and other stocks. Vote "Outperform" if you believe PCYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.